STK39-mediated amplification of γ-H2A.X promotes homologous recombination and contributes to PARP inhibitor resistance

被引:0
|
作者
Xu, Yi [1 ,2 ]
Li, Changying [1 ,2 ]
Yin, Huan [1 ,2 ]
Nowsheen, Somaira [3 ]
Xu, Xin [1 ,2 ]
Kang, Wenjuan [1 ,2 ]
Liu, Xin [1 ,2 ]
Chen, Lifeng [4 ]
Lou, Zhenkun [5 ]
Yi, Junlin [1 ,2 ]
Deng, Min [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,State Key Lab Mol Oncol, Panjiayuan Nanli 17, Beijing 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing 100021, Peoples R China
[3] Univ Calif San Diego, Dept Dermatol, 9500 Gilman Dr, San Diego, CA 92122 USA
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Gynecol, 79 Qingchun Rd, Pujiang 322200, Peoples R China
[5] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
基金
美国国家科学基金会;
关键词
SYNTHETIC LETHALITY; DNA; STK39; ATM; REPAIR; MDC1; SPAK; INVASION; BRCA1; 53BP1;
D O I
10.1093/nar/gkae1099
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The phosphorylation of histone H2A.X into gamma H2A.X is a crucial early event in the DNA damage response, marking DNA damage sites and initiating repair processes. While ATM kinase is traditionally recognized as the primary mediator of H2A.X phosphorylation, our study identifies serine/threonine kinase 39 (STK39) as a novel enhancer of this critical signaling pathway. We demonstrate that after DNA damage, STK39 undergoes phosphorylation by the ATM kinase, facilitating its interaction with the Mre11-Rad50-Nbs1 complex and subsequent recruitment to chromatin. This recruitment enables STK39 to further phosphorylate H2A.X, thus amplifying gamma H2A.X production and promoting homologous recombination repair. Notably, we observe a significant upregulation of STK39 in pancreatic adenocarcinoma (PAAD) tissues, correlating with heightened resistance to PARPi therapy. Furthermore, we demonstrate the synergistic efficacy of combining STK39 inhibition with PARP inhibitors in suppressing and reversing PAAD growth. This study not only provides new insights into the molecular dynamics of H2A.X phosphorylation but also highlights the therapeutic potential of targeting STK39 to enhance PARPi sensitivity in PAAD (created with BioRender). [GRAPHICS]
引用
收藏
页码:13881 / 13895
页数:15
相关论文
共 3 条
  • [1] Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
    Ning, Jian-Fang
    Stanciu, Monica
    Humphrey, Melissa R.
    Gorham, Joshua
    Wakimoto, Hiroko
    Nishihara, Reiko
    Lees, Jacqueline
    Zou, Lee
    Martuza, Robert L.
    Wakimoto, Hiroaki
    Rabkin, Samuel D.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [2] Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination
    Cao, Kun
    Wang, Ruonan
    Li, Lianhai
    Liao, Yuting
    Hu, Xiao
    Li, Ruixue
    Liu, Xiuwen
    Xiong, Xing-dong
    Wang, Yanjie
    Liu, Xinguang
    ONCOGENE, 2024, 43 (01) : 35 - 46
  • [3] Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
    Park, Pyoung Hwa
    Yamamoto, Tomomi M.
    Li, Hua
    Alcivar, Allen L.
    Xia, Bing
    Wang, Yifan
    Bernhardy, Andrea J.
    Turner, Kristen M.
    Kossenkov, Andrew V.
    Watson, Zachary L.
    Behbakht, Kian
    Casadei, Silvia
    Swisher, Elizabeth M.
    Mischel, Paul S.
    Johnson, Neil
    Bitler, Benjamin G.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (02) : 602 - 613